Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study

Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study

Abstract Background Eribulin or capecitabine monotherapy is the next cytotoxic chemotherapy option for patients with metastatic or recurrent breast cancer who have previously received an anthracycline or a taxane. However, it is unclear what factors can guide the selection of eribulin or capecitabin...

Full description

Bibliographic Details
Main Authors: Shigemasa Takamizawa, Tatsunori Shimoi, Natsuko Satomi-Tsushita, Shu Yazaki, Toshihiro Okuya, Yuki Kojima, Hitomi Sumiyoshi-Okuma, Tadaaki Nishikawa, Maki Tanioka, Kazuki Sudo, Emi Noguchi, Kan Yonemori
Format: Article
Language:English
Published: BMC 2022-01-01
Series:BMC Cancer
Subjects:
Breast cancer
Capecitabine
Chemotherapy
Eribulin
Neutrophil-to-lymphocyte ratio
NLR
Online Access:https://doi.org/10.1186/s12885-021-09112-9

Internet

https://doi.org/10.1186/s12885-021-09112-9

Similar Items